Synlogic Inc (SYBX) Receives Average Rating of “Buy” from Analysts

Synlogic Inc (NASDAQ:SYBX) has been assigned an average rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $17.79.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised Synlogic from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Saturday, November 17th. Wedbush reaffirmed an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. Oppenheimer set a $18.00 price target on Synlogic and gave the company a “buy” rating in a research report on Monday, November 12th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Synlogic in a research report on Tuesday, November 13th. Finally, Citigroup raised their price target on Synlogic to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th.

Synlogic stock opened at $9.05 on Friday. The firm has a market cap of $222.67 million, a price-to-earnings ratio of -1.54 and a beta of 2.62. Synlogic has a one year low of $7.20 and a one year high of $15.00.

Synlogic (NASDAQ:SYBX) last posted its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.21. The firm had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.20 million. Synlogic had a negative net margin of 1,912.74% and a negative return on equity of 39.07%. Equities analysts anticipate that Synlogic will post -2.2 EPS for the current fiscal year.

In other news, insider Paul Francis Miller sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $12.55, for a total value of $37,650.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 12,000 shares of company stock worth $135,390. 23.30% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. acquired a new stake in Synlogic during the third quarter worth about $145,000. Rhumbline Advisers bought a new position in Synlogic during the third quarter worth about $212,000. Northern Trust Corp bought a new position in Synlogic during the first quarter worth about $249,000. TIAA CREF Investment Management LLC bought a new position in Synlogic during the third quarter worth about $251,000. Finally, Teachers Advisors LLC bought a new position in Synlogic during the third quarter worth about $290,000. 80.90% of the stock is currently owned by institutional investors and hedge funds.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: What are earnings reports?

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply